Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

Studied

SURPASS-3 compared once-weekly tirzepatide with daily, treat-to-target insulin degludec.

Who / model

The analysis included 1437 insulin-naive adults with type 2 diabetes inadequately controlled by metformin, with or without an SGLT2 inhibitor.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

At week 52, tirzepatide reduced body weight by 7·5 kg to 12·9 kg, while insulin degludec increased it by 2·3 kg.

Limits

The trial was open-label. Treatment discontinuation because of adverse events was more common with tirzepatide, and methodological quality was not formally appraised here.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary